Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction.

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Treating hypertension reduces the rates of myocardial infarction, stroke, and renal disease; however, clinical trial experience suggests that monotherapy is not likely to be successful for achieving goal blood pressure (BP) levels in many hypertensive patients. In multiple recent clinical trials including various subsets of hypertensive patients, the achievement of BP goal has typically required the combination of 2 or more medications, particularly in patients with BP levels>160/100 mm Hg. When initiating combination therapy for hypertension, careful consideration must be given to the choice of medication. Clinical trial evidence has shown the efficacy of various combinations of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and diuretics in reducing BP and cardiovascular risk. Ongoing trials should provide additional guidance on the optimal choice of combination regimens in specific clinical settings.

Original languageEnglish (US)
Pages (from-to)26-32
Number of pages7
JournalJournal of clinical hypertension (Greenwich, Conn.)
Issue number11 Suppl 4
StatePublished - Nov 2007

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction.'. Together they form a unique fingerprint.

Cite this